Company Overview and News

11
Australian shares hit highest since January 2008, led by banks; NZ up

2018-06-20 theedgemarkets
BENGALURU (June 20): Australian shares closed at their highest level in nearly 10½ years, driven by a rally in banks, but a fall for Telstra after it flagged major job cuts and asset sales in a "strategic reset" capped Wednesday's gains.
WBC CMXHF WBC TLS WEBNF CHEOF WBK TTRAF TLSYY CHEOY SML

2
Australian telecom Telstra to ax 8,000 jobs to save $740M

2018-06-20 nzherald.co.nz
CANBERRA, Australia (AP) — Telstra Corp., Australia's largest telecommunications company, has announced plans to ax 8,000 jobs — one in four employees — over three years in a bid to save 1 billion Australian dollars ($740 million).
TLS TTRAF TLSYY

2
Telstra is the ASX Most Active as it outlines staff chopping block plan

2018-06-20 proactiveinvestors.com.au
Telstra Ltd (ASX:TLS) is by far the most active stock on the market today, trading 74 million shares by noon, with the valuation wiped down by 5.5% to $2.75.
AGO TLS TLS ATLGF AGODY TTRAF TLSYY

30
Telstra not interested in bidding for 3rd telco slot

2018-05-27 bworldonline
AUSTRALIAN telecommunications company Telstra Corp. Ltd. said it will not join the bidding process for the “third” major telecommunications player in the Philippines.
SMCP1 GTMEY GLOPP TTRAF TLSYY SMGBY SMGBF GLO SMC2B SMC2A SMC SMC2D SMC2C TLS SMC2F SMC2E GTMEF GLOPA

2
Telstra Smart Wi-Fi Booster review: bust black spots on a budget

2018-05-21 smh.com.au
Tackling black spots around your home, Telstra's Smart Wi-Fi Booster ensures your wireless gadgets are never caught offline.
TLS TTRAF TLSYY

12
Tesla Board Opposition Builds as Proxy Firm Slams Bad Governance - Bloomberg

2018-05-16 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
GJV FOX NWS NWSA TLS TTRAF TLSYY FOXA

4
TiVo's (TIVO) CEO Enrique Rodriguez on Q1 2018 Results - Earnings Call Transcript

2018-05-11 seekingalpha
Good afternoon. My name is Sarah and I will be your conference operator today. At this time, I would like to welcome everyone to the TiVo 2018 First Quarter Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions]
TLS TTRAF TLSYY TIVO

2
Buddy Platform turns to Dicker Data for distribution as Telstra bows out

2018-04-19 proactiveinvestors.com.au
Buddy Platform Ltd (ASX:BUD) will look to Dicker Data Ltd (ASX:DDR) as its primary distribution channel for Buddy Ohm in Australia.
TLS TLS POTTF IM BUD TTRAF TLSYY DDR

23
Top 50 Communication Services Stocks For April By Yield And Target Gains

2018-04-13 seekingalpha
Overseas telecom firms remained at the top by gains this month as North American telcos were mid-bound in analyst 1yr. targeting.
BCE VOD VOD VODPF RNRTY NZTCY SPKKY SPK NZTCF TTRAF TLSYY

9
UPDATE 1-Nine loses Australia cricket broadcast rights to rivals Seven, Foxtel

2018-04-13 reuters
April 13 (Reuters) - Nine Entertainment Co Holdings has lost Cricket Australia’s broadcast rights to rival Seven West Media and pay television firm Foxtel.
WANHY GJV SWM NWS NWSA TLS TTRAF TLSYY WANHF

2
eCompareMo uses AI to help loan, card seekers

2018-03-15 bworldonline
C88 FINANCIAL Technologies Pte Ltd., owner and operator of website eCompareMo, is using artificial intelligence and data technologies to serve its customers as it looks to launch products to help Filipino consumers looking to tap financial services.
TLS TTRAF TLSYY

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...